Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsAntonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
Life of this patent
Estimating the term…
Abstract
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
Claims16
A double-stranded ribonucleic acid (dsRNA), wherein said dsRNA comprises a sense strand and an antisense strand, wherein each of the sense strand and the antisense strand is 15-30 nucleotides in length, and wherein the antisense strand comprises a region of complementarity which is complementary to an mRNA encoding Serum amyloid A (SAA) and is complementary to at least 15 contiguous nucleotides of SEQ ID NO:
- 233.
Dependencies are inferred from the claim text.